Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corporation (OTC PINK: HALB) demonstrated promising results in eradicating E. coli bacteria from cerebral spinal fluid using its patented extracorporeal methodology, achieving a 96% elimination rate in under 20 minutes, compared to 7-10 days with conventional antibiotics. This advancement could enhance recovery in patients suffering from meningitis and blood sepsis, conditions responsible for approximately 40,000 deaths annually in the U.S. Halberd’s technology aims to minimize adverse effects associated with standard treatments and prevent antibiotic resistance.
Halberd Corporation (OTC PINK:HALB) announced plans to enter the Metaverse through the creation of non-fungible tokens (NFTs) aimed at monetizing its intellectual properties, including patents and trade secrets. The company is negotiating with experts in the NFT space to identify growth opportunities and manage essential partnerships. Shareholders will independently purchase these NFTs via personalized electronic wallets, granting them tokenized rights to specific intellectual properties. This initiative aims to enhance liquidity for shareholders, providing dual sources of ownership in the company.
Halberd Corporation (OTC PINK:HALB) announced successful in vitro elimination of C-Reactive Protein (CRP) from cerebral spinal fluid using tuned laser light. This follows their success in targeting ten antigens associated with PTSD and neurodegenerative diseases. With major depression affecting 21 million Americans, Halberd aims to develop a process to lower CRP levels linked to clinical depression. CEO William Hartman highlighted ongoing laboratory experimentation, upcoming animal tests, and plans for commercialization of their findings.
Halberd Corporation (OTC PINK:HALB) advances its research by appointing Dr. Ravi Venkata Durvasula, an esteemed infectious disease expert, to its advisory team. Following the successful elimination of the Top 10 Target Antigens related to neurodegenerative diseases, Halberd aims to extend its patented extracorporeal technology to combat infectious diseases. Dr. Durvasula, affiliated with the Mayo Clinic, brings extensive expertise, having authored over 100 publications. Halberd's leadership expressed confidence in Dr. Durvasula's contributions as the company prepares for crucial animal testing.
Halberd Corporation (OTC PINK:HALB) announced the addition of Dr. Chester R. Cooper from Youngstown State University to its technical team. Dr. Cooper, a microbiology expert, has been instrumental in E. coli testing and analysis. He brings extensive experience with 47 peer-reviewed publications and has held various academic positions. His efforts will focus on advancing Halberd's research on neurodegenerative diseases and developing methods for eradicating bacterial infections using lasers and radio frequency.
Halberd Corporation (OTC PINK:HALB) announced its SARS-CoV-2 antibody has superior binding capability to the Omicron variant, outperforming five FDA-approved monoclonal antibodies in competitive testing. Results indicate that Halberd's antibody (11D7) shows significant binding with increased concentrations, while competitors demonstrated near-zero binding. CEO William Hartman noted the company's focus on neurodegenerative diseases but is open to partnerships to commercialize the COVID technology. The press release emphasizes Halberd's unique patented process for potential treatment against pandemic variants.
Halberd Corporation (OTC PINK:HALB) has achieved a significant breakthrough in treating neurodegenerative diseases by successfully eliminating glutamate from cerebral spinal fluid. This advancement allows control over ten disease-associated antigens, opening new treatment possibilities for conditions like PTSD, Alzheimer's, and more. The company intends to validate efficacy through animal testing and is pursuing FDA certification. Additionally, Halberd is collaborating with universities and research organizations to advance its initiatives. This solution could benefit millions suffering from neurodegenerative disorders.
Halberd Corporation (OTC PINK:HALB) has successfully eliminated 100% of Tau protein from cerebral spinal fluid in less than 20 minutes using its patented laser exposure process. This marks the ninth of ten neurodegenerative disease target antigens the company has addressed. Dr. Mitchell S. Felder highlighted that Halberd's approach effectively removes disease precursors without introducing foreign substances. CEO William A. Hartman expressed confidence in eliminating the remaining target antigen, glutamate, and aims to seek partnerships for effective treatments in various neurodegenerative diseases.
Halberd Corporation (OTC PINK:HALB) has achieved a breakthrough in the treatment of Alzheimer's Disease by selectively eliminating Tau proteins from a mixture without affecting non-target cytokines. This was accomplished using Halberd's proprietary extracorporeal laser exposure process in synthetic cerebral spinal fluid, a substitute for human CSF. Dr. Mitchell S. Felder described this as a landmark achievement that opens new avenues for treating various diseases with precision. Halberd holds exclusive rights to three issued patents and continues to file related patent applications to secure its innovations.
Halberd Corporation (OTC PINK: HALB) provides an overview of its achievements and goals for 2022. The company focuses on biomedical R&D, targeting neurodegenerative diseases, with a proprietary treatment methodology. Key milestones include successful eradication of top antigens linked to diseases, the addition of patents, and plans for joint ventures and government grants. Forward goals encompass completing independent audits, filing a FORM-10, and expanding outreach and product lines. Halberd aims to enhance its technical capabilities and brand recognition to assure success for shareholders.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
